CompletedNot Applicable

Drug-coated Balloon in de Novo Chronic Total Occlusions

Austria, Belgium, Croatia309 participantsStarted 2012-12-15

Plain-language summary

The CTO-DENOVO study is a multicenter registry of consecutive patients with de novo coronary chronic total occlusions (CTO) undergoing successful CTO recanalization with the use of drug-coated balloon (DCB)-only strategy. The primary endpoint is target lesion failure at 6 months. The secondary endpoints are: 1) late lumen loss on follow-up angiography, and 2) minimal lumen area on follow-up intravascular ultrasound.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * de novo coronary CTO undergoing successful recanalization with the use of DCB-only strategy at the occlusion site Exclusion Criteria: * de novo coronary CTO undergoing successful recanalization with the use of DES at the occlusion site * in-stent CTO

What they're measuring

Target lesion failure

Timeframe: 6 months

Trial details

NCT IDNCT05977842

SponsorNational Institute of Cardiology, Warsaw, Poland

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2024-12-15

View on ClinicalTrials.gov More Coronary Artery Disease trials